⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 1, 2026Open Access

Functional aplication of the iCasp9 suicide gene system as a safety mechanism for CAR-T Cells

Bernardo Vasconcelos Martín Bonamino João Steimbach Eduardo Correia

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the iCasp9 suicide gene system as a safety mechanism in CAR-T cell therapies.
Utilized the iCasp9 system in CAR-T cell design.
Conducted evaluations at the International Symposium on Immunobiologicals.
Examined effects on safety and efficacy.
Demonstrated enhanced safety profile of CAR-T cells with iCasp9.
Notable reduction in adverse effects related to CAR-T therapy.

Implication

Explores a safety mechanism for CAR-T cells using the iCasp9 system, suggesting enhanced control.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vasconcelos et al. (2026) studied this question.

synapsesocial.com/papers/69fd7cd4bfa21ec5bbf05b15 https://doi.org/10.35259/isi.2026_76387

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Generation of anti-GD2 CAR-T cellsOriginal Research · 2026
2Evaluation of single-stranded DNA knock-in and base editing in combination with sleeping beauty transposon for a non-viral allogeneic 19BBz CAR-T generationOriginal Research · 2026
3Generation of CAR-NK92mi cells as an off-the-shelf approach using nonviral minimizedOriginal Research · 2026
4Development of bispecific nanobody-derived CARs targeting b-cell leukemia markers: CD19, CD20, and CD22Original Research · 2026
5Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T CellsOriginal Research · 2017 · 251 citations

Development of targeted immunomodulatory VLPs to enhance antigen presentation and potentiate the antitumor immune response2026
Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system2024
Abstract LT01: Identifying Optimal Tumour-specific Promoters for CRISPR/Cas9 Engineering of Armoured CAR T Cells with Enhanced Safety and Efficacy2025